Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. [electronic resource]
Producer: 20010531Description: 1343-52 p. digitalISSN:- 0022-1899
- AIDS Vaccines -- genetics
- Adolescent
- Adult
- Avipoxvirus -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Double-Blind Method
- Female
- Genetic Vectors
- HIV Envelope Protein gp120 -- genetics
- HIV Infections -- prevention & control
- HIV Protease -- genetics
- HIV-1 -- immunology
- Humans
- Immunization Schedule
- Immunization, Secondary
- Male
- Middle Aged
- Risk Factors
- Safety
- T-Lymphocytes, Cytotoxic -- immunology
- Vaccines, Attenuated
- Vaccines, Synthetic
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.